Physician profile
Fernando E Membreno
NPI 1942233929
$257,873.82
in general payments reported to CMS, 2019-2025
19 companies · $116K in 2025
The $116K reported for 2025 was more than what 96% of Transplant Hepatology providers received nationally (typical 2025 total: $508).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $11K · 2021: $16K · 2022: $11K · 2023: $16K · 2024: $48K · 2025: $116K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $147K · Travel and Lodging: $23K · Food and Beverage: $7,086 · Consulting Fee: $2,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $147,168.50 |
| Travel and Lodging | $23,338.31 |
| Food and Beverage | $7,085.58 |
| Consulting Fee | $2,820.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $151,537.38 | 2019-2025 | Epclusa, Livdelzi, Vemlidy |
| Madrigal Pharmaceuticals | $67,708.32 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $36,842.13 | 2024-2025 | Iqirvo, Bylvay |
| Mallinckrodt Hospital Products INC. | $380.11 | 2022-2025 | Terlivaz |
| Melinta Therapeutics, LLC | $263.59 | 2022-2023 | Rezzayo |
| Exact Sciences Corporation | $252.39 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $245.88 | 2021-2024 | |
| Boston Scientific Corporation | $185.71 | 2024-2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial), Therasphere Y90 Glass Microspheres 10 Gbq |
| Dova Pharmaceuticals | $113.63 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.26 | 2025 | |
| Fujifilm Healthcare Americas Corporation | $57.74 | 2025 | |
| Novo Nordisk INC | $41.05 | 2025 | Wegovy |
| Abbvie INC. | $27.83 | 2025 | |
| Medtronic, INC. | $20.73 | 2025 | Emprint |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $17.38 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Membreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.